Skip to main content
SupplementScience

Benefits of Avocado Soy Unsaponifiables (ASU)

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

Evidence-Based Benefits

  • OA pain reduction — Maheu et al. (1998, n=163) demonstrated ASU 300mg daily significantly reduced pain and disability in knee and hip OA over 6 months, reducing NSAID use by 50%
  • Structural joint protection — Maheu et al. (2014, n=399) showed ASU 300mg daily reduced progression of joint space narrowing in hip OA over 3 years in a large placebo-controlled trial
  • Cartilage-protective mechanism — ASU inhibits matrix metalloproteinases (MMP-2, MMP-3, MMP-13) and IL-1β, preventing enzymatic cartilage breakdown at the molecular level
  • Stimulates cartilage repair — ASU upregulates TGF-β and aggrecan expression in chondrocytes, promoting synthesis of new cartilage matrix components
  • Reduces NSAID dependence — multiple trials show ASU-treated patients significantly reduce or eliminate their use of NSAIDs and analgesics over 3-6 months

What the Research Says

ASU has one of the strongest evidence bases among plant-derived joint supplements. Maheu et al. (1998) established symptomatic efficacy in a 6-month RCT, with a notable 50% reduction in NSAID use. The same group conducted a pivotal 3-year trial (Maheu et al., 2014, n=399) demonstrating structural benefits — ASU significantly slowed hip joint space narrowing compared to placebo, providing disease-modifying evidence. Appelboom et al. (2001) confirmed benefits in a 3-month RCT. A meta-analysis by Christensen et al. (2008) included ASU among supplements with evidence supporting clinical efficacy. In France, ASU is sold as the prescription drug Piascledine 300 and has over 20 years of clinical use. ESCEO and OARSI guidelines include ASU as a recommended treatment option for OA.

Related Conditions

OsteoarthritisJoint Pain
Full Avocado Soy Unsaponifiables (ASU) Guide

References

  1. (). Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis & Rheumatism. DOI
  2. (). Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases. DOI
  3. (). Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. Scandinavian Journal of Rheumatology. DOI
  4. (). Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis and Cartilage. DOI